Page header

Recommendation of the President – Jaypirca (pirtobrutinib)

On 30 April 2026,  the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 50/2026 on the inclusion of the medicinal product Jaypirca (pirtobrutinib) in the reimbursement program B.79 “Treatment of patients with chronic lymphocytic leukemia (ICD-10: C91.1)”

Publication in Public Information Bulletin (BIP) >>